How profitable is Amarin (AMRN) stock?
Amarin has a market capitalization of $1.19 billion and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or $0.03 on an earnings per share basis.
What is Amarin Corporation plc known for?
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.
When does Amarin earnings call for 2019?
AMRN earnings call for the period ending December 31, 2019. AMRN earnings call for the period ending September 30, 2019. Primary metrics and data points about Amarin. Learn more about CAPS!
Is Amarin's stock near a bottom?
The Fool has written over 500 articles on Amarin. The biopharma's stock could be near a bottom after last month's double-digit decline. An activist investor revealed that it held a small stake in the company.
See more
Is AMRN stock a good buy?
The 7 analysts offering 12-month price forecasts for Amarin Corporation PLC have a median target of 3.00, with a high estimate of 9.00 and a low estimate of 1.50. The median estimate represents a +127.27% increase from the last price of 1.32.
What is AMRN price target?
Stock Price Target AMRNHigh$9.00Median$3.00Low$1.50Average$3.57Current Price$1.34
Who owns AMRN stock?
Largest shareholders include Sarissa Capital Management LP, Baker Bros. Advisors Lp, Eversept Partners, LP, SCP Investment, LP, Avoro Capital Advisors LLC, Stonepine Capital Management, LLC, Millennium Management Llc, Clearbridge Investments, LLC, Morgan Stanley, and Rock Springs Capital Management LP.
Does Amarin pay dividends?
Amarin (NASDAQ: AMRN) does not pay a dividend.
Will Amarin stock recover?
On average, Wall Street analysts predict that Amarin's share price could reach $3.00 by May 6, 2023. The average Amarin stock price prediction forecasts a potential upside of 85.19% from the current AMRN share price of $1.62.
Will Amarin be acquired?
US firm Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals) has agreed to acquire UK-headquartered Amarin Corp's US unit and most of Amarin Pharmaceuticals Inc's US products for a consideration of $38 million.
Who owns Amarin Pharmaceuticals?
NovartisThe Medicines Company was acquired by Novartis for $9.7 billion despite having no revenue (versus $600 million for Amarin) and no FDA approval at the time (Amarin has FDA and EU approval). Amarin has a star drug and would be a prime takeover target for Big Pharma.
What pharmaceutical company makes vascepa?
AmarinAmarin is a rapidly growing, innovative pharmaceutical company focused on commercializing and developing therapeutics to cost-effectively improve cardiovascular health. Amarin's lead product, VASCEPA, is a prescription drug.
How much does Amarin make?
When is Amarin earnings call?
Amarin has a market capitalization of $1.59 billion and generates $614.06 million in revenue each year. The biopharmaceutical company earns $-18,000,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.
Nasdaq Global Market
How can I listen to Amarin's earnings call? Amarin will be holding an earnings conference call on Thursday, August 5th at 7:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-481-4010 with passcode "401474".
Environmental, Social, and Governance Rating
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
